Evidence map›Paper›PMID 29805949›Full record

ArticleCureus2018

CyberKnife Radiosurgery of Skull-base Tumors: A UK Center Experience.

Hannah P Wilson, Patricia M Price, Keyoumars Ashkan, Andrew Edwards, Melanie M Green, Timothy Cross, Ronald P Beaney, Rhiannon Davies, Amen Sibtain, Nick P Plowman and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Hannah P WilsonDepartment of Surgery and Cancer, Imperial College London, London, GBR.
Patricia M PriceDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Keyoumars AshkanDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Andrew EdwardsDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Melanie M GreenDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Timothy CrossDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Ronald P BeaneyDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Rhiannon DaviesDepartment of Neuro Oncology, Guy's and St. Thomas' Hospital, London, GBR.
Amen SibtainDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Nick P PlowmanDepartment of Radiation Oncology, The Harley Street Clinic, London, GBR.
Christy GoldsmithClinical Oncology, Guy's and St. Thomas' Hospital, London, GBR.
Whiteley Clinic · GBSt Thomas' Hospital · GBImperial College London · GBSt. Thomas Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aim was to evaluate patient individualized Cyberknife® treatment for heterogeneous skull-base tumors. Patients treated between 2009 and 2013 at The Harley Street Clinic were studied. In total, 66 patients received 15-30 Gy in 1-5 fractions to a median planning target volume (PTV) of 6.4 cc, including patients with secondary, multiple, residual and recurrent tumors, and those with tumors of uncertain pathological type. Outcome analysis was pragmatically restricted to 35 patients who had single, primary tumors treated with curative intent, and sufficient diagnostic and outcome information. Sixteen vestibular schwannoma patients with median PTV 3.8 cc (range 0.81-19.6) received 18-25 Gy in 3-5 fractions: 81% showed no acute toxicity, 50% reported no late toxicity, 71% of symptoms were stable/improved and local control was 100% at 11.4 months median follow-up. Twelve meningioma patients with median PTV of 5.5 cc (range 0.68-22.3) received 17-30 Gy in 1-5 fractions: 83% experienced no acute toxicity, 33% reported no late toxicity, 88% of symptoms were stable/improved and local control was 100% at 22.1 months median follow-up. Seven patients with other tumor types with median PTV of 24.3 cc (range 7.6-100.5) received 15-28.5 Gy in 1-5 fractions: 57% experienced no acute toxicity, 57% reported no late toxicities, 66% of symptoms were stable and local control was 43% at 14.9 months median follow-up. When tumor types were considered together, smaller tumors (PTV < 6.4 cc) showed reduced acute toxicity (p = 0.01). Overall, smaller benign tumors showed low acute toxicity, excellent local control, and good symptom management: a focus on enhanced neurological preservation may refine outcomes. For other tumor types outcome was encouraging: a focus on optimal dose and fractionation scheduling may reduce toxicity and improve local control. Individual patient experiences are detailed where valuable lessons were gained for optimizing local control and minimizing toxicity.

Indexed as

cyberknifefractionated radiotherapyintracranialradiosurgeryskull basestereotactictreatment outcomestumors

Identifiers

PMID29805949
PMCPMC5969819
OpenAlexW2794478933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.